Canada markets close in 3 hours 16 minutes

Ginkgo Bioworks Holdings, Inc. (DNA)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
3.0900-0.1400 (-4.33%)
As of 12:44PM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • B
    I added for a second time today.
  • I
    950,000 more shares bought today by ark
  • W
    $AMRS conversation
    $DNA • Morgan Stanley launched its coverage on the cell programming platform company, Ginkgo Bioworks (NYSE:DNA), on Tuesday with an Equal Weight recommendation citing limited near-term outperformance due to macro concerns and the early stage of the pipeline.
    • The analysts led by Tejas Savant argue that DNA is positioned to cater to an estimated $2.4T market for bioengineered products with downstream value sharing with clients.
    • Morgan Stanley notes that in terms of 2023E sales, DNA currently trades at ~12.8x EV, out of which 50% is attributed to the downstream equity share. Citing its assumptions on the value of the downstream equity share, the firm indicated that the company trades at a premium to peers.
    • However, they argue that DNA deserves only an in-line multiple as the early stage of the business and peer-lagging operating margin profile offset positives such as the significant total addressable market in synthetic biology.
  • D
    David St. Hubbins
    Cathie bought another million shares today.
  • M
    Ginkgo Bioworks has just announced two new acquisitions today: Biotech companies Altar and Circularis.
  • I
    Close to one million shares ARK bought today!
  • B
    I would love to hear the company explain the reasoning for this last financing.
  • M
    Higher lows and higher highs...Very bullish signals even on red days.
  • t
    43mil sh were short from Aug 15 to Sept 15. Now short interest stands at over 187mil shares...according to YAHOO...the shorts should get nervous to short $3 stock....there will be a squeeze coming probably after DNA announces earnings mid Nov....DNA has added lots of new platforms and companies to its rev stream...let's see if DNA can become the Amazon of syn. bio....
  • B
    Two very smart acquisition’s announced today. Building a very strong company.
  • L
    Ginkgo Bioworks (NYSE:DNA) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $5.00 price target on the stock. This represents a 49.7% upside from the current price of $3.34.
  • B
    DNA is currently my favorite long term pick for price appreciation.
  • A
    Always Right
    The whole market says "accumulation" today. And DNA shows more deliberate buys...steady but heavy. We appear to be in a great spot as the market experiments with the notion of risk. As far as growth companies go, this is a good one. Just needed a green-light on buying growth.
  • A
    the only problem with this company is they have 1.19 billion shares outstanding that's a lot of shares is a company worth $6 billion dollars will know when the stock goes to $6
  • S
    Tuck in acquisitions appear sensible, but announcement of 500M shelf offering makes no sense to me, given their cash position and current depressed stock price. Not the best time to be doing secondarys. Wonder what they are thinking
  • M
    M. Smith
    There we go!!
  • A
    Always positive
    Let’s go DNA👍
  • P
    there were 2 upgrades after last earnings $6 and $14.50...yesterday MS started DNA with equalweight and $5 target price...will there be more upgrades after next earnings around Mid Nov???
  • B
    Just added some more shares to my position.
  • R
    Can’t find the right DNA to trade? I have the fix for free